N Blank1, U Hegenbart2, S Schönland2. 1. Amyloidose-Zentrum, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland. norbert.blank@med.uni-heidelberg.de. 2. Amyloidose-Zentrum, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland.
Abstract
BACKGROUND: Systemic amyloidoses are rare protein deposition disorders, which are often diagnosed in an advanced stage of the disease due to non-specific symptoms. Any chronic inflammatory disease can lead to an AA-type amyloidosis. AIM: This paper summarizes the current state of the art of diagnosis and treatment of AA amyloidosis and presents data from the past 10 years of our amyloidosis center. MATERIAL AND METHODS: Our data represents an analysis of our cohort of patients with amyloidosis and a selective research in the PubMed database for AA amyloidosis. RESULTS: The underlying diseases comprise autoinflammatory syndromes, polyarthritis, and chronic inflammatory bowel and lung diseases. Renal organ involvement is the most prevalent in AA amyloidosis. It can be detected early through the evaluation of proteinuria. The treatment depends on the individual underlying disease. Patients without an associated inflammatory disease are considered to have idiopathic AA amyloidosis and empiric treatment is mandatory. DISCUSSION: Survival of this fatal disease has recently improved due to the new diagnostic tools and treatment options; however, early diagnosis plays a crucial role in the prevention of end-stage renal failure. New therapeutic strategies aim to remove existing amyloid deposits.
BACKGROUND: Systemic amyloidoses are rare protein deposition disorders, which are often diagnosed in an advanced stage of the disease due to non-specific symptoms. Any chronic inflammatory disease can lead to an AA-type amyloidosis. AIM: This paper summarizes the current state of the art of diagnosis and treatment of AA amyloidosis and presents data from the past 10 years of our amyloidosis center. MATERIAL AND METHODS: Our data represents an analysis of our cohort of patients with amyloidosis and a selective research in the PubMed database for AA amyloidosis. RESULTS: The underlying diseases comprise autoinflammatory syndromes, polyarthritis, and chronic inflammatory bowel and lung diseases. Renal organ involvement is the most prevalent in AA amyloidosis. It can be detected early through the evaluation of proteinuria. The treatment depends on the individual underlying disease. Patients without an associated inflammatory disease are considered to have idiopathic AA amyloidosis and empiric treatment is mandatory. DISCUSSION: Survival of this fatal disease has recently improved due to the new diagnostic tools and treatment options; however, early diagnosis plays a crucial role in the prevention of end-stage renal failure. New therapeutic strategies aim to remove existing amyloid deposits.
Entities:
Keywords:
Amyloidosis; Biologic; Cytokine; Dialysis; Early diagnosis; Proteinuria
Authors: Jean D Sipe; Merrill D Benson; Joel N Buxbaum; Shu-ichi Ikeda; Giampaolo Merlini; Maria J M Saraiva; Per Westermark Journal: Amyloid Date: 2014-09-29 Impact factor: 7.141
Authors: J C H van der Hilst; T Yamada; H J M Op den Camp; J W M van der Meer; J P H Drenth; A Simon Journal: Rheumatology (Oxford) Date: 2008-09-24 Impact factor: 7.580
Authors: G Palladini; P Milani; A Foli; M Vidus Rosin; M Basset; F Lavatelli; M Nuvolone; L Obici; S Perlini; G Merlini Journal: Leukemia Date: 2014-07-25 Impact factor: 11.528
Authors: J Paul Simons; Raya Al-Shawi; Stephan Ellmerich; Ivana Speck; Samrina Aslam; Winston L Hutchinson; Palma P Mangione; Petra Disterer; Janet A Gilbertson; Toby Hunt; David J Millar; Shane Minogue; Karl Bodin; Mark B Pepys; Philip N Hawkins Journal: Proc Natl Acad Sci U S A Date: 2013-08-19 Impact factor: 11.205
Authors: Laura M Dember; Philip N Hawkins; Bouke P C Hazenberg; Peter D Gorevic; Giampaolo Merlini; Irena Butrimiene; Avi Livneh; Olga Lesnyak; Xavier Puéchal; Helen J Lachmann; Laura Obici; Robert Balshaw; Denis Garceau; Wendy Hauck; Martha Skinner Journal: N Engl J Med Date: 2007-06-07 Impact factor: 91.245